Literature DB >> 3211503

Natural course of melanocytic tumors of the iris.

C Territo1, C L Shields, J A Shields, J J Augsburger, R P Schroeder.   

Abstract

The authors received the charts and photographs of 175 patients who had suspicious melanocytic lesions of the iris and who were followed without treatment. Only eight (4.6%) of these lesions showed clinical evidence of enlargement during follow-up intervals of 1 to 12 years (mean, 4.7 years). Features that were associated with enlargement of the lesion included medial location of the mass on the iris and presence of pigment dispersion onto the adjacent iris and anterior chamber angle structures. Features that were unassociated with growth of the lesion included patient age and sex, intraocular pressure, iris color, tumor size and vascularity, and presence of pupillary distortion, ectropion iridis, and sector cataract. From these results, recommendations are made which can assist the ophthalmologist in the management of pigmented iris lesions.

Entities:  

Mesh:

Year:  1988        PMID: 3211503     DOI: 10.1016/s0161-6420(88)33022-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  16 in total

Review 1.  Don't it make my blue eyes brown: heterochromia and other abnormalities of the iris.

Authors:  I G Rennie
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

2.  Progression of an iris melanoma over 41 years.

Authors:  D G Charteris
Journal:  Br J Ophthalmol       Date:  1990-09       Impact factor: 4.638

3.  Hyphema from Iris Melanocytoma.

Authors:  Neel D Pasricha; Michael I Seider
Journal:  Ocul Oncol Pathol       Date:  2018-10-25

4.  Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma.

Authors:  M Tsimpida; J Hungerford; A Arora; V Cohen
Journal:  Eye (Lond)       Date:  2011-09-23       Impact factor: 3.775

Review 5.  Prognosis in ocular melanoma.

Authors:  J Hungerford
Journal:  Br J Ophthalmol       Date:  1989-09       Impact factor: 4.638

6.  [Iridal color changing in ocular masquerade syndrome].

Authors:  S Waibel; K Pillunat; L Pillunat
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

7.  Irradiating iris tumours.

Authors:  I Rennie
Journal:  Br J Ophthalmol       Date:  1995-04       Impact factor: 4.638

8.  Factors associated with elevated intraocular pressure in eyes with iris melanoma.

Authors:  C L Shields; M A Materin; J A Shields; E Gershenbaum; A D Singh; A Smith
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

9.  Iris nevi and melanomas: a clinical follow-up study.

Authors:  F van Klink; R J de Keizer; M J Jager; H M Kakebeeke-Kemme
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

10.  Treatment of non-resectable malignant iris tumours with custom designed plaque radiotherapy.

Authors:  C L Shields; J A Shields; P De Potter; A D Singh; C Hernandez; L W Brady
Journal:  Br J Ophthalmol       Date:  1995-04       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.